Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 11Dysport

02 1Dysport Aesthetic

03 1Dysport Therapeutic

PharmaCompass

01

Brand Name : Dysport

Abobotulinumtoxin A

arrow
FNCE
Not Confirmed

Brand Name : Dysport

arrow
FNCE
Not Confirmed

Abobotulinumtoxin A

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2020 Revenue in Millions : 427

2019 Revenue in Millions : 470

Growth (%) : -9

blank

02

Brand Name : Dysport

Abobotulinumtoxin A

arrow
FNCE
Not Confirmed

03

Brand Name : Dysport

Abobotulinumtoxin A

arrow
FNCE
Not Confirmed

04

Brand Name : Dysport

Abobotulinumtoxin A

arrow
FNCE
Not Confirmed

05

Brand Name : Dysport Aesthetic

Abobotulinumtoxin A

arrow
FNCE
Not Confirmed

Brand Name : Dysport Aesthetic

arrow
FNCE
Not Confirmed

Abobotulinumtoxin A

Main Therapeutic Indication : Dermatology

Currency : USD

2024 Revenue in Millions : 414

2023 Revenue in Millions : 412

Growth (%) : 0

blank

06

Brand Name : Dysport

Abobotulinumtoxin A

arrow
FNCE
Not Confirmed

07

Brand Name : Dysport Therapeutic

Abobotulinumtoxin A

arrow
FNCE
Not Confirmed

Brand Name : Dysport Therapeutic

arrow
FNCE
Not Confirmed

Abobotulinumtoxin A

Main Therapeutic Indication : Neurology

Currency : USD

2024 Revenue in Millions : 301

2023 Revenue in Millions : 288

Growth (%) : 5

blank

08

Brand Name : Dysport

Abobotulinumtoxin A

arrow
FNCE
Not Confirmed

09

Brand Name : Dysport

Abobotulinumtoxin A

arrow
FNCE
Not Confirmed

Brand Name : Dysport

arrow
FNCE
Not Confirmed

Abobotulinumtoxin A

Main Therapeutic Indication : Lower Limb Spasticity

Currency : USD

2016 Revenue in Millions : 302

2015 Revenue in Millions : 297

Growth (%) : 2

blank

10

Brand Name : Dysport

Abobotulinumtoxin A

arrow
FNCE
Not Confirmed

Brand Name : Dysport

arrow
FNCE
Not Confirmed

Abobotulinumtoxin A

Main Therapeutic Indication : Lower Limb Spasticity

Currency : USD

2017 Revenue in Millions : 407

2016 Revenue in Millions : 353

Growth (%) : 15

blank